Akebia Therapeutics swings to Q3 2026 net loss of $14.4 million from year-earlier profit
AKBA•Akebia Therapeutics reported a third-quarter 2026 net loss of $14.4 million, compared with net income of $0.5 million a year earlier. Revenue fell 37% to $36.9 million as Auryxia sales declined, while Vafseo patients more than doubled to approximately 11,500.
1. Quarterly results
Akebia Therapeutics swung to a third-quarter 2026 net loss of $14.4 million from net income of $0.5 million a year earlier. Total revenues fell 37% year-over-year to $36.9 million, driven by lower Auryxia revenues. Auryxia net product revenues dropped 53% to $20 million, while Vafseo revenues rose to $14.8 million.
2. Vafseo and trial update
Patients receiving Vafseo more than doubled from a year earlier to approximately 11,500 at quarter-end. The VOCAL trial met its primary endpoint, demonstrating vadadustat’s non-inferiority to erythropoiesis-stimulating agents in maintaining hemoglobin.
